[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease.
Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, Lussier FZ, Schroeder FA, DuBois JM, Hightower BG, Gilbert TM, Zürcher NR, Wang C, Hopewell R, Chakravarty M, Savard M, Thomas E, Mohaddes S, Farzin S, Salaciak A, Tullo S, Cuello AC, Soucy JP, Massarweh G, Hwang H, Kobayashi E, Hyman BT, Dickerson BC, Guiot MC, Szyf M, Gauthier S, Hooker JM, Rosa-Neto P.
Nat Commun. 2022 Jul 19;13(1):4171. doi: 10.1038/s41467-022-30653-5.
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H.
Nat Rev Neurol. 2022 Jul;18(7):400-418. doi: 10.1038/s41582-022-00665-2. Epub 2022 May 18.
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease.
Nilsson J, Ashton NJ, Benedet AL, Montoliu-Gaya L, Gobom J, Pascoal TA, Chamoun M, Portelius E, Jeromin A, Mendes M, Zetterberg H, Rosa-Neto P, Brinkmalm A, Blennow K.
Alzheimers Res Ther. 2022 Jun 4;14(1):78. doi: 10.1186/s13195-022-01021-8.
18F-MK-6240 tau-PET in genetic frontotemporal dementia.
Levy JP, Bezgin G, Savard M, Pascoal TA, Finger E, Laforce R, Sonnen JA, Soucy JP, Gauthier S, Rosa-Neto P, Ducharme S.
Brain. 2022 Jun 3;145(5):1763-1772. doi: 10.1093/brain/awab392.
Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer’s disease.
Terada T, Therriault J, Kang MS, Savard M, Pascoal TA, Lussier F, Tissot C, Wang YT, Benedet A, Poltronetti NM, Ottoy J, Arias JF, Bezgin G, Matsudaira T, Bunai T, Obi T, Tsukada H, Ouchi Y, Rosa-Neto P.
Eur J Neurol. 2022 May;29(5):1324-1334. doi: 10.1111/ene.15246. Epub 2022 Jan 22.
Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic.
Kang MS, Shin M, Ottoy J, Aliaga AA, Mathotaarachchi S, Quispialaya K, Pascoal TA, Collins DL, Chakravarty MM, Mathieu A, Sandelius Å, Blennow K, Zetterberg H, Massarweh G, Soucy JP, Cuello AC, Gauthier S, Waterston M, Yoganathan N, Lessard E, Haqqani A, Rennie K, Stanimirovic D, Chakravarthy B, Rosa-Neto P.
J Cereb Blood Flow Metab. 2022 May;42(5):788-801. doi: 10.1177/0271678X211035625. Epub 2021 Aug 11.
Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease.
Cassidy CM, Therriault J, Pascoal TA, Cheung V, Savard M, Tuominen L, Chamoun M, McCall A, Celebi S, Lussier F, Massarweh G, Soucy JP, Weinshenker D, Tardif C, Ismail Z, Gauthier S, Rosa-Neto P.
Neuropsychopharmacology. 2022 Apr;47(5):1128-1136. doi: 10.1038/s41386-022-01293-6. Epub 2022 Feb 17.
A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer’s disease.
Brum WS, de Bastiani MA, Bieger A, Therriault J, Ferrari-Souza JP, Benedet AL, Saha-Chaudhuri P, Souza DO, Ashton NJ, Zetterberg H, Pascoal TA, Karikari T, Blennow K, Rosa-Neto P, Zimmer ER; Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Alzheimers Dement (N Y). 2022 Mar 13;8(1):e12270. doi: 10.1002/trc2.12270. eCollection 2022.
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET.
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S, Lussier FZ, Chamoun M, Tudorascu DL, Stevenson J, Rahmouni N, Poltronetti NM, Pallen V, Bezgin G, Kang MS, Mathotaarachchi SS, Wang YT, Fernandez Arias J, Ferreira PCL, Ferrari-Souza JP, Vanmechelen E, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P.
EBioMedicine. 2022 Feb;76:103837. doi: 10.1016/j.ebiom.2022.103837. Epub 2022 Feb 6.